Cargando…
Extended Infusion of Meropenem in Neonatal Sepsis: A Historical Cohort Study
This single-center historical cohort study investigated the effectiveness and safety of extended infusion (EI) compared with short-term infusion (STI) of meropenem in neonatal sepsis. Patient electronic health records from Peking University Third Hospital (1 December 2011–1 April 2021) were screened...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8944670/ https://www.ncbi.nlm.nih.gov/pubmed/35326804 http://dx.doi.org/10.3390/antibiotics11030341 |
_version_ | 1784673774354825216 |
---|---|
author | Cao, Guangna Zhou, Pengxiang Zhang, Hua Sun, Bangkai Tong, Xiaomei Xing, Yan |
author_facet | Cao, Guangna Zhou, Pengxiang Zhang, Hua Sun, Bangkai Tong, Xiaomei Xing, Yan |
author_sort | Cao, Guangna |
collection | PubMed |
description | This single-center historical cohort study investigated the effectiveness and safety of extended infusion (EI) compared with short-term infusion (STI) of meropenem in neonatal sepsis. Patient electronic health records from Peking University Third Hospital (1 December 2011–1 April 2021) were screened. Neonates diagnosed with sepsis and treated with meropenem in the neonatal intensive care unit were included (256 patients) as STI (0.5 h, 129 patients) and EI (2–3 h, 127 patients) groups. Three-day clinical effectiveness and three-day microbial clearance were considered the main outcomes. Univariate and multivariate analyses were performed. Baseline characteristics were similar in both groups. EI of meropenem was associated with a significantly higher 3-day clinical effectiveness rate (0.335 (0.180, 0.623), p = 0.001) and 3-day microbial clearance (4.127 (1.235, 13.784), p = 0.021) than STI, with comparable safety. Subgroup analyses showed that neonates with very low birth weight benefited from EI in terms of 3-day clinical effectiveness rate (75.6% versus 56.6%, p = 0.007), with no significant difference in the 3-day clinical effectiveness (85.1% versus 78.3%, p = 0.325) and microbial clearance (6% versus 5%, p > 0.999) rates between 3 h and 2 h infusions. Thus, EI of meropenem may be associated with better effectiveness and comparable safety in treating neonatal sepsis than STI. Nonetheless, historically analyzed safety evaluation might be biased, and these findings need confirmation in randomized controlled trials of larger sample sizes. |
format | Online Article Text |
id | pubmed-8944670 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-89446702022-03-25 Extended Infusion of Meropenem in Neonatal Sepsis: A Historical Cohort Study Cao, Guangna Zhou, Pengxiang Zhang, Hua Sun, Bangkai Tong, Xiaomei Xing, Yan Antibiotics (Basel) Article This single-center historical cohort study investigated the effectiveness and safety of extended infusion (EI) compared with short-term infusion (STI) of meropenem in neonatal sepsis. Patient electronic health records from Peking University Third Hospital (1 December 2011–1 April 2021) were screened. Neonates diagnosed with sepsis and treated with meropenem in the neonatal intensive care unit were included (256 patients) as STI (0.5 h, 129 patients) and EI (2–3 h, 127 patients) groups. Three-day clinical effectiveness and three-day microbial clearance were considered the main outcomes. Univariate and multivariate analyses were performed. Baseline characteristics were similar in both groups. EI of meropenem was associated with a significantly higher 3-day clinical effectiveness rate (0.335 (0.180, 0.623), p = 0.001) and 3-day microbial clearance (4.127 (1.235, 13.784), p = 0.021) than STI, with comparable safety. Subgroup analyses showed that neonates with very low birth weight benefited from EI in terms of 3-day clinical effectiveness rate (75.6% versus 56.6%, p = 0.007), with no significant difference in the 3-day clinical effectiveness (85.1% versus 78.3%, p = 0.325) and microbial clearance (6% versus 5%, p > 0.999) rates between 3 h and 2 h infusions. Thus, EI of meropenem may be associated with better effectiveness and comparable safety in treating neonatal sepsis than STI. Nonetheless, historically analyzed safety evaluation might be biased, and these findings need confirmation in randomized controlled trials of larger sample sizes. MDPI 2022-03-04 /pmc/articles/PMC8944670/ /pubmed/35326804 http://dx.doi.org/10.3390/antibiotics11030341 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Cao, Guangna Zhou, Pengxiang Zhang, Hua Sun, Bangkai Tong, Xiaomei Xing, Yan Extended Infusion of Meropenem in Neonatal Sepsis: A Historical Cohort Study |
title | Extended Infusion of Meropenem in Neonatal Sepsis: A Historical Cohort Study |
title_full | Extended Infusion of Meropenem in Neonatal Sepsis: A Historical Cohort Study |
title_fullStr | Extended Infusion of Meropenem in Neonatal Sepsis: A Historical Cohort Study |
title_full_unstemmed | Extended Infusion of Meropenem in Neonatal Sepsis: A Historical Cohort Study |
title_short | Extended Infusion of Meropenem in Neonatal Sepsis: A Historical Cohort Study |
title_sort | extended infusion of meropenem in neonatal sepsis: a historical cohort study |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8944670/ https://www.ncbi.nlm.nih.gov/pubmed/35326804 http://dx.doi.org/10.3390/antibiotics11030341 |
work_keys_str_mv | AT caoguangna extendedinfusionofmeropeneminneonatalsepsisahistoricalcohortstudy AT zhoupengxiang extendedinfusionofmeropeneminneonatalsepsisahistoricalcohortstudy AT zhanghua extendedinfusionofmeropeneminneonatalsepsisahistoricalcohortstudy AT sunbangkai extendedinfusionofmeropeneminneonatalsepsisahistoricalcohortstudy AT tongxiaomei extendedinfusionofmeropeneminneonatalsepsisahistoricalcohortstudy AT xingyan extendedinfusionofmeropeneminneonatalsepsisahistoricalcohortstudy |